ReviewThe Journal of allergy and clinical immunology2025
Precision medicine for asthma treatment: Unlocking the potential of the epigenome and microbiome.
Review in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune and inflammatory mechanisms in asthma: insights into epigenetic modifications.Frontiers in immunology · 2025Pooled it
- Evolution, hotspots, and future directions of artificial intelligence in asthma research: a Web of Science-based bibliometric analysis [2016-2026].Journal of thoracic disease · 2026Article
- Update in asthma management: A narrative review of recent advances, challenges, and future directions.Clinical medicine (London, England) · 2026Review
- Multi-Dimensional Perspective of the Gene and Environmental Interaction in Asthma.Clinical reviews in allergy & immunology · 2026Review
- Multi-Ancestry Epigenome-Wide Meta-Analysis Identifies Novel Bulk and Cell-Type-Specific Epigenetic Markers of Asthma with Severe Exacerbations.medRxiv : the preprint server for health sciences · 2026Article
- The Nasal Microbiome and Associations With Environmental Exposures and Respiratory Health.Allergy · 2026Article
- Nasopharyngeal Microbiome-Epigenome-Wide Association Analysis in Infants With Severe Bronchiolitis.Allergy · 2026Article
- Effect of the Arg16Gly βAllergy · 2026Article
- Modulation of the NF-κB signaling pathway by the combined strategy of tocilizumab and dexamethasone for asthma therapy.Respiratory research · 2026Article
- Editorial: Dust mite allergy: immunological mechanisms, environmental impact, genetic susceptibility, diagnosis, therapeutic strategies & preventive measures.Frontiers in allergy · 2026Article
- Advancements in diagnosis, preventive care, and future directions in the holistic management of pediatric asthma.Frontiers in pediatrics · 2026Review
- Epigenetics in asthma: implications for treatable traits.Frontiers in allergy · 2026Review
- Heterogeneity and molecular mechanisms of early-life wheeze.The Journal of allergy and clinical immunology · 2025Article
- Article
- Yangke powder alleviates OVA-induced allergic asthma by inhibiting the PI3K/AKT/NF-κB signaling pathway.Chinese medicine · 2025Article
- The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications.Signal transduction and targeted therapy · 2025Review
- Role of the TGF-β cytokine and its gene polymorphisms in asthma etiopathogenesis.Frontiers in allergy · 2025Review
- The gut-lung axis in asthma: microbiota-driven mechanisms and therapeutic perspectives.Frontiers in microbiology · 2025Review
- Association Between Chronic Neck Pain and Increased Risk of Chronic Respiratory Diseases in Middle-Aged and Elderly Chinese Adults: A Cohort Study Based on CHARLS.Journal of pain research · 2025Article
- Differences in the DNA methylome of T cells in adults with asthma of varying severity.Clinical epigenetics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Asthma is a leading worldwide biomedical concern. Patients can experience life-threatening worsening episodes (exacerbations) usually controlled by anti-inflammatory and bronchodilator drugs. However, substantial heterogeneity in treatment response exists, and a subset of patients with unresolved asthma carry the major burden of this disease. The study of the epigenome and microbiome might bridge the gap between human genetics and environmental exposure to partially explain the heterogeneity in drug response. This review aims to provide a critical examination of the existing literature on the microbiome and epigenetic studies examining associations with asthma treatments and drug response, highlight convergent pathways, address current challenges, and offer future perspectives. Current epigenetic and microbiome studies have shown the bilateral relationship between asthma pharmacologic interventions and the human epigenome and microbiome. These studies, focusing on corticosteroids and to a lesser extent on bronchodilators, azithromycin, immunotherapy, and mepolizumab, have improved the understanding of the molecular basis of treatment response and identified promising biomarkers for drug response prediction. Immune and inflammatory pathways (eg, IL-2, TNF-α, NF-κB, and C/EBPs) underlie microbiome-epigenetic associations with asthma treatment, representing potential therapeutic pathways to be targeted. A comprehensive evaluation of these omics biomarkers could significantly contribute to precision medicine and new therapeutic target discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.